Lauren M Castner1, Madsen Zimbric1, Shannon Cahalan1, Corey Powell2, Lindsay J Caverly3. 1. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA. 2. Statistics, Computing, and Analytics Research, University of Michigan, Ann Arbor, MI, USA. 3. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: caverlyl@med.umich.edu.
Abstract
BACKGROUND: Obligate and facultative anaerobic bacteria are prevalent in cystic fibrosis (CF) airways. Increases in anaerobe relative abundance have been associated with CF pulmonary exacerbations (PEx); however, the impact of antibiotic treatment of anaerobes during PEx is unknown. We hypothesized that PEx treated with antibiotics with activity against anaerobes would improve outcomes compared to antibiotics without anaerobic activity. METHODS: This was a single-center, retrospective study of people with CF, ages 6 years and older, treated with intravenous (IV) antibiotics for PEx. IV antibiotics were classified as either broad or minimal anaerobic activity. PEx treated with broad anaerobe coverage were propensity-score matched to PEx treated with minimal anaerobic coverage. The primary outcome, % of baseline % predicted forced expiratory volume in one second (ppFEV1) recovered, was compared between antibiotic categories with a linear mixed model. The secondary outcome, time to next PEx, was assessed using a Prentice Williams Petersen model. RESULTS: 514 PEx from 182 patients were included. Broad anaerobe coverage was used in 27% of PEx, and was used more often for older patients (p < 0.001) with worse baseline ppFEV1 (p < 0.001), and with Achromobacter (p < 0.001) or Burkholderia infections (p = 0.002). In the matched PEx, broad anaerobe coverage was not a significant predictor of % of baseline ppFEV1 recovered (∆ppFEV1 = -2.4, p = 0.09). Broad anaerobe coverage was also not a significant predictor of time to next PEx (HR 0.89, 95% CI 0.7-1.13, p = 0.35). CONCLUSIONS: In this single center, retrospective study, antibiotics with broad activity against anaerobes were not associated with improved outcomes of CF PEx.
BACKGROUND: Obligate and facultative anaerobic bacteria are prevalent in cystic fibrosis (CF) airways. Increases in anaerobe relative abundance have been associated with CF pulmonary exacerbations (PEx); however, the impact of antibiotic treatment of anaerobes during PEx is unknown. We hypothesized that PEx treated with antibiotics with activity against anaerobes would improve outcomes compared to antibiotics without anaerobic activity. METHODS: This was a single-center, retrospective study of people with CF, ages 6 years and older, treated with intravenous (IV) antibiotics for PEx. IV antibiotics were classified as either broad or minimal anaerobic activity. PEx treated with broad anaerobe coverage were propensity-score matched to PEx treated with minimal anaerobic coverage. The primary outcome, % of baseline % predicted forced expiratory volume in one second (ppFEV1) recovered, was compared between antibiotic categories with a linear mixed model. The secondary outcome, time to next PEx, was assessed using a Prentice Williams Petersen model. RESULTS: 514 PEx from 182 patients were included. Broad anaerobe coverage was used in 27% of PEx, and was used more often for older patients (p < 0.001) with worse baseline ppFEV1 (p < 0.001), and with Achromobacter (p < 0.001) or Burkholderia infections (p = 0.002). In the matched PEx, broad anaerobe coverage was not a significant predictor of % of baseline ppFEV1 recovered (∆ppFEV1 = -2.4, p = 0.09). Broad anaerobe coverage was also not a significant predictor of time to next PEx (HR 0.89, 95% CI 0.7-1.13, p = 0.35). CONCLUSIONS: In this single center, retrospective study, antibiotics with broad activity against anaerobes were not associated with improved outcomes of CF PEx.
Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191
Authors: Edith T Zemanick; Brandie D Wagner; Charles E Robertson; Richard C Ahrens; James F Chmiel; John P Clancy; Ronald L Gibson; William T Harris; Geoffrey Kurland; Theresa A Laguna; Susanna A McColley; Karen McCoy; George Retsch-Bogart; Kurtis T Sobush; Pamela L Zeitlin; Mark J Stevens; Frank J Accurso; Scott D Sagel; J Kirk Harris Journal: Eur Respir J Date: 2017-11-16 Impact factor: 16.671
Authors: Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume Journal: Thorax Date: 2015-04-24 Impact factor: 9.139
Authors: Bojana Mirković; Michelle A Murray; Gillian M Lavelle; Kevin Molloy; Ahmed Abdul Azim; Cedric Gunaratnam; Fiona Healy; Dubhfeasa Slattery; Paul McNally; Joe Hatch; Matthew Wolfgang; Michael M Tunney; Marianne S Muhlebach; Rosaleen Devery; Catherine M Greene; Noel G McElvaney Journal: Am J Respir Crit Care Med Date: 2015-12-01 Impact factor: 21.405
Authors: Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall Journal: Am J Respir Crit Care Med Date: 2009-09-03 Impact factor: 21.405
Authors: Maria T Nelson; Daniel J Wolter; Alexander Eng; Eli J Weiss; Anh T Vo; Mitchell J Brittnacher; Hillary S Hayden; Sumedha Ravishankar; Gilbert Bautista; Anina Ratjen; Marcella Blackledge; Sharon McNamara; Laura Nay; Cheryl Majors; Samuel I Miller; Elhanan Borenstein; Richard H Simon; John J LiPuma; Luke R Hoffman Journal: Thorax Date: 2020-07-06 Impact factor: 9.139
Authors: Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman Journal: Sci Rep Date: 2015-05-14 Impact factor: 4.379
Authors: Alya A Heirali; Matthew L Workentine; Nicole Acosta; Ali Poonja; Douglas G Storey; Ranjani Somayaji; Harvey R Rabin; Fiona J Whelan; Michael G Surette; Michael D Parkins Journal: Microbiome Date: 2017-05-05 Impact factor: 14.650
Authors: Lisa A Carmody; Lindsay J Caverly; Bridget K Foster; Mary A M Rogers; Linda M Kalikin; Richard H Simon; Donald R VanDevanter; John J LiPuma Journal: PLoS One Date: 2018-03-09 Impact factor: 3.240
Authors: Cynthia B Silveira; Ana G Cobián-Güemes; Carla Uranga; Jonathon L Baker; Anna Edlund; Forest Rohwer; Douglas Conrad Journal: Int J Mol Sci Date: 2021-11-07 Impact factor: 5.923